期刊
BLOOD
卷 121, 期 15, 页码 2996-3004出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-08-448068
关键词
-
类别
资金
- National Cancer Institute, National Institutes of Health, Department of Health and Human Services
Therapy-related acute myeloid leukemia (tAML) is a rare but highly fatal complication of cytotoxic chemotherapy. Despite major changes in cancer treatment, data describing tAML risks over time are sparse. Among 426 068 adults initially treated with chemotherapy for first primary malignancy (9 US population-based cancer registries, 1975-2008), we identified 801 tAML cases, 4.70 times more than expected in the general population (P < .001). Over time, tAML risks increased after chemotherapy for non-Hodgkin lymphoma (n = 158; Poisson regression P-trend < .001), declined for ovarian cancer (n = 72; P-trend < .001), myeloma (n = 62; P-trend = .02), and possibly lung cancer (n = 65; P-trend = .18), and were significantly heterogeneous for breast cancer (n = 223; P-homogeneity = .005) and Hodgkin lymphoma (n = 58; P-homogeneity = .007). tAML risks varied significantly by age at first cancer and latency and were non-significantly heightened with radiotherapy for lung, breast, and ovarian cancers. We identified newly emerging elevated tAML risks in patients treated with chemotherapy since 2000 for esophageal, cervical, prostate, and possibly anal cancers; and since the 1990s for bone/joint and endometrial cancers. Using long-term, population-based data, we observed significant variation in tAML risk with time, consistent with changing treatment practices and differential leukemogenicity of specific therapies. tAML risks should be weighed against the benefits of chemotherapy, particularly for new agents and new indications for standard agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据